SCHEMBL16409221

SCHEMBL16409221

COC(=O)c1ccc([C@@H]2C[C@@H](O)CCN2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 4/20 0.47
TSHR P16473 4/20 0.47
HSD17B10 Q99714 3/20 0.47
GAA P10253 3/20 0.47
HPGD P15428 2/20 0.47
CASP1 P29466 2/20 0.47
CASP7 P55210 2/20 0.47
ATM Q13315 2/20 0.47
GLA P06280 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTT P42858 1/20 0.42
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25076566 1.00 ALDH1A1 (0.47) ALDH1A1KDM4ETSHRHSD17B10GAA
SCHEMBL28325217 1.00 ALDH1A1 (0.47) ALDH1A1KDM4ETSHRHSD17B10GAA
SCHEMBL29148946 1.00 ALDH1A1 (0.47) ALDH1A1KDM4ETSHRHSD17B10GAA
SCHEMBL25620691 1.00 ALDH1A1 (0.47) ALDH1A1KDM4ETSHRHSD17B10GAA
SCHEMBL17782270 0.86 KDM4E (0.47) ALDH1A1KDM4ETSHRHSD17B10GAA
SCHEMBL16409304 0.86 KDM4E (0.47) ALDH1A1KDM4ETSHRHSD17B10GAA
SCHEMBL29213767 0.84 ALDH1A1 (0.49) ALDH1A1KDM4ETSHRHSD17B10GAA
SCHEMBL25076567 0.84 ALDH1A1 (0.49) ALDH1A1KDM4ETSHRHSD17B10GAA
SCHEMBL16401331 0.84 ALDH1A1 (0.46) ALDH1A1KDM4ETSHRHSD17B10GAA
SCHEMBL25077043 0.84 ALDH1A1 (0.49) ALDH1A1KDM4ETSHRHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10093663-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof NOVARTIS AG (CH) 2018-10-09 US disclosed
EP-3299365-A1 PIPERIDINYL-INDOLE DERIVATIVES COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF Novartis AG (CH) 2018-03-28 EP disclosed
EP-3299365-A1 PIPERIDINYL-INDOLE DERIVATIVES COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF Novartis AG (CH) 2018-03-28 EP disclosed
US-20180009795-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2018-01-11 US disclosed
US-20180009795-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2018-01-11 US disclosed
EP-3022192-B1 PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS NOVARTIS AG (CH) 2017-10-11 EP disclosed
EP-3022192-B1 PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS NOVARTIS AG (CH) 2017-10-11 EP disclosed
US-9682968-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof NOVARTIS AG (CH) 2017-06-20 US disclosed
US-9682968-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof NOVARTIS AG (CH) 2017-06-20 US disclosed
US-9682968-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof NOVARTIS AG (CH) 2017-06-20 US disclosed
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2016-06-02 US disclosed
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2016-06-02 US disclosed
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof NOVARTIS AG (CH) 2016-06-02 US disclosed
WO-2015009616-A1 PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS NOVARTIS AG (CH) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152605-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof CFB, TFPI, TFPI2 ALDH1A1 1827/4885KDM4E 3083/4885TSHR 2719/4885
US-10093663-B2 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof CFB, C5, TFPI ALDH1A1 1590/4885KDM4E 2332/4885TSHR 2710/4885
US-20180009795-A1 Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof CFB, C5, TFPI ALDH1A1 1590/4885KDM4E 2332/4885TSHR 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.